IN8BIO, Inc. Files 8-K on Executive Compensation
Ticker: INAB · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, filing, financials
TL;DR
IN8BIO filed an 8-K for executive comp changes & financials.
AI Summary
On August 30, 2024, IN8bio, Inc. filed an 8-K report detailing changes in its executive compensation arrangements. The filing also includes financial statements and exhibits, though specific details of these arrangements or financial figures were not provided in the excerpt.
Why It Matters
Changes in executive compensation can signal shifts in company strategy or performance, potentially impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Filings related to executive compensation and financial statements can introduce uncertainty or reveal performance metrics that affect stock price.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- August 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39692 (filing_id) — SEC File Number
- 82-5462585 (tax_id) — IRS Employer Identification No.
- New York (location) — Principal Executive Offices
- Incysus Therapeutics, Inc. (company) — Former Company Name
- 20180510 (date) — Date of Name Change
FAQ
What specific changes were made to the executive compensation arrangements?
The filing indicates changes to executive compensation arrangements, but the specific details of these changes are not provided in the excerpt.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is August 30, 2024.
What is the company's state of incorporation?
The company, IN8bio, Inc., is incorporated in Delaware.
What is the SEC file number for IN8bio, Inc.?
The SEC file number for IN8bio, Inc. is 001-39692.
What was the former name of IN8bio, Inc.?
The former name of IN8bio, Inc. was Incysus Therapeutics, Inc., with a name change date of May 10, 2018.
Filing Stats: 674 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-09-06 16:05:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d806767d8k.htm (8-K) — 28KB
- d806767dex101.htm (EX-10.1) — 9KB
- d806767dex102.htm (EX-10.2) — 9KB
- d806767dex103.htm (EX-10.3) — 9KB
- d806767dex104.htm (EX-10.4) — 9KB
- d806767dex105.htm (EX-10.5) — 9KB
- g806767g0906005532477.jpg (GRAPHIC) — 3KB
- 0001193125-24-215154.txt ( ) — 219KB
- inab-20240830.xsd (EX-101.SCH) — 3KB
- inab-20240830_lab.xml (EX-101.LAB) — 18KB
- inab-20240830_pre.xml (EX-101.PRE) — 11KB
- d806767d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Amendment to Employment Agreement, by and between the Company and William Ho, dated as of August 30, 2024. 10.2 Amendment to Employment Agreement, by and between the Company and Trishna Goswami, dated as of August 30, 2024. 10.3 Amendment to Employment Agreement, by and between the Company and Lawrence Lamb, dated as of August 30, 2024. 10.4 Amendment to Employment Agreement, by and between the Company and Patrick McCall, dated as of August 30, 2024. 10.5 Amendment to Employment Agreement, by and between the Company and Kate Rochlin, dated as of August 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: September 6, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)